Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. Leaders and professionals tend to navigate decisions and challenges through familiar ...

Over the past few weeks several reports of mysterious drone sightings have emerged across New Jersey, sparking alarm among ...

Beam Therapeutics Inc.’s BEAM share price has dipped by 11.15%, which has investors questioning if this is right time to buy.

Beam Therapeutics' specialization lies in base editing which is potentially the best-in-class gene editing technology. This technology allows precise modifications without cutting the DNA strands.